ImmuPharma : FDA confirms Type-C meeting date of 7th June 2023 for Phase 2/3 adaptive study of Lupuzor™ in lupus

FDA confirms Type-C meeting date of 7th June 2023 for Phase 2/3 adaptive study of Lupuzor™ in lupus

20th April 2023 - 10:20 am

ImmuPharma PLC , the specialist drug... | April 20, 2023

Related Keywords

Tim Mccarthy ,Drug Administration ,Immupharma Plc Stock Exchange ,News ,Information ,Press Release ,Fda ,Onfirms ,Meeting ,Gate ,F ,Ith ,Pune ,023 ,Or ,Hase ,Adaptive ,Study ,N ,0th ,Pril ,Immupharma ,Lc ,The ,Pecialist Imm Gb0033711010 ,